Ying Zhang

发表

PEGylation Confers Greatly Extended Half-Life and Attenuated Immunogenicity to Recombinant Methioninase in Primates

Jinbao Xu, E. Frenkel, R. Hoffman, 2004, Cancer Research.

Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19

M. Bassetti, S. Bhagani, N. Ohmagari, 2022, Annals of Internal Medicine.

Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19

S. Bhagani, J. Butterton, J. Arribas, 2021, NEJM Evidence.

Development of a robust functional cell-based assay for replacing the rabbit blood sugar bioidentity test of insulin glargine drug substance.

J. Yie, Joseph Sergi, Ying Zhang, 2020, Journal of pharmaceutical and biomedical analysis.

Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a–Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders

R. Petric, E. Gane, D. Larrey, 2013, Antimicrobial Agents and Chemotherapy.

Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.

Ying Zhang, C. Stedman, A. Horban, 2011, Journal of hepatology.

Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.

P. Marcellin, N. Terrault, P. Ferenci, 2013, Gastroenterology.

Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis

Y. Guan, Lai Wei, J. Jia, 2020, Journal of viral hepatitis.

Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.

T. Merigan, G. D. Miralles, J. Bartlett, 2004, The Journal of infectious diseases.

T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.

G. D. Miralles, C. Cohen, M. Greenberg, 2005, The Journal of infectious diseases.

1159. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-Dose Clinical Trial

M. Kelly, J. Butterton, E. Roilides, 2021, Open Forum Infectious Diseases.

Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis

Daniel S Spellman, Amy S. Espeseth, A. Espeseth, 2021, EBioMedicine.

Impact of Molnupiravir Treatment on Patient-Reported Coronavirus Disease 2019 (COVID-19) Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial.

C. Brotons, A. Puenpatom, M. Brown, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects

G. D. Miralles, I. Patel, E. Dejesus, 2006, AIDS.

511. Treatment with Molnupiravir in the MOVe-In and MOVe-Out Clinical Trials Results in an Increase in Transition Mutations Across the SARS-CoV-2 Genome

A. Therien, N. Murgolo, J. Butterton, 2021, Open Forum Infectious Diseases.